Genetic Testing

Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program

Award Seeks to Demonstrate Feasibility of Manufacturing mRNA Vaccines in Only 7 Days  STONY BROOK, NY / ACCESSWIRE / April…

2 years ago

Applied DNA Announces 1-For-20 Reverse Stock Split

STONY BROOK, NY / ACCESSWIRE / April 22, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the Company),…

2 years ago

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

80% of people diagnosed with anxiety, depression report losing years or decades of timeSALT LAKE CITY, April 17, 2024 (GLOBE…

2 years ago

GeneType Clinicians’ Adoption Growing – Sales up 5-Fold Year on Year

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader…

2 years ago

Multicancer Screening Market Projected to Reach $2.72 billion by 2030 – Exclusive Report by 360iResearch

PUNE, India, April 15, 2024 /PRNewswire/ -- The report titled "Multicancer Screening Market by Product (AI and Machine Learning-Based Platforms,…

2 years ago

CancerIQ CEO Feyi Ayodele Named to Modern Healthcare’s 2024 Innovators List

CHICAGO--(BUSINESS WIRE)--#aheadofcancer--CancerIQ is proud to announce that co-founder and CEO Feyi Ayodele was recognized by Modern Healthcare as one of…

2 years ago

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight testSALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE)…

2 years ago

EVENT – Empowering Women Through Knowledge; Humanise Health & GeneType Launch “Know Your Risk”

MELBOURNE, Australia, April 08, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader…

2 years ago

Shifa Health Marks 21 Years of Transformative Mental Health Care

A Celebration of Innovation, Compassion, and Community EngagementEVERETT, WA / ACCESSWIRE / April 3, 2024 / Shifa Health, a leading…

2 years ago

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight…

2 years ago